Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library
Portfolio Pulse from Lara Goldstein
Clinical-stage biotech company Cybin Inc. (NYSE:CYBN) has received a U.S. patent for deuterated tryptamines, including the novel psilocybin analog in the company’s CYB003 investigational program and novel DMT analog in its CYB004 program. The patent is expected to provide exclusivity until 2041 and covers methods of treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). Private biopharma company Psilera Inc. has received a USPTO notice of allowance for its filed patent application around novel compositions of matter and pharmaceutical compositions.
August 16, 2023 | 7:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin Inc. has secured a patent for deuterated tryptamines, bolstering its IP portfolio and providing exclusivity until 2041.
The patent secured by Cybin Inc. covers novel compounds and treatment methods, which could potentially give the company a competitive edge in the market. This could lead to increased investor interest and potentially a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100